Prostate Cancer Therapeutics Global Market Report 2025

Description

Prostate cancer therapeutics encompass a range of medical treatments and interventions designed to manage, control, or eliminate prostate cancer, a type of cancer that forms in the prostate gland of men. These therapies aim to slow disease progression, alleviate symptoms, improve quality of life, and, in some instances, achieve remission.

The primary types of therapies in prostate cancer treatment include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Hormonal therapy is a treatment that modifies hormone levels in the body to address conditions such as cancer or hormonal imbalances. This therapy includes various drug classes such as androgen receptor inhibitors, GnRH receptor antagonists, PARP inhibitors, immune checkpoint inhibitors, and more, which can be administered either orally or through injection. These therapies are distributed via hospital pharmacies, retail pharmacies, and online sales, serving various end users, including clinics, hospitals, and other medical facilities.

The prostate cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer therapeutics market statistics, including prostate cancer therapeutics industry global market size, regional shares, competitors with a prostate cancer therapeutics market share, detailed prostate cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer therapeutics industry. This prostate cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer therapeutics market size has grown strongly in recent years. It will grow from $11.92 billion in 2024 to $13.00 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to several factors, including the rising global incidence of prostate cancer, increased awareness of early cancer screening and diagnostic programs, the growing elderly male population, and a higher demand for personalized and targeted therapies.

The prostate cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as rising healthcare expenditure in emerging economies, increasing investments in oncology drugs, greater availability of advanced imaging and diagnostic tools, and the growing adoption of minimally invasive and non-surgical treatments. Key trends in the forecast period include advancements in targeted cancer therapies, the integration of precision cancer medicine, the development of technology-driven diagnostic imaging tools, progress in radioligand-based treatments, and continued advancements in immunotherapy for prostate cancer.

The increasing incidence of prostate cancer is expected to drive the growth of the prostate cancer therapeutics market. Prostate cancer, a disease where malignant cells form in the prostate gland, primarily affects older men. The rise in prostate cancer incidences is largely attributed to the aging population, as the risk of developing the disease increases significantly with age. Longer life expectancy also means more men are living long enough to develop the condition. Prostate cancer therapeutics aim to manage the disease by targeting cancer cells, slowing its progression, and improving the quality of life through treatments such as surgery, radiation, hormone therapy, and newer options such as immunotherapy. For example, in October 2024, the National Health Service (NHS) in the UK reported that cancer diagnoses among men increased by 7% in 2022, from 167,917 to 180,877 cases. A significant portion of this rise was attributed to prostate cancer, which saw a more than 25% increase, reaching 54,732 cases. This growing incidence of prostate cancer is driving the expansion of the prostate cancer therapeutics market.

Leading companies in the prostate cancer therapeutics market are introducing innovative solutions, such as oral once-a-day pills for advanced prostate cancer, to enhance patient compliance and treatment outcomes. These oral pills are taken daily and manage metastatic castration-resistant prostate cancer by inhibiting the effects of testosterone on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based pharmaceutical company, launched Rexigo, India's first oral once-a-day pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies works by rapidly suppressing testosterone, controlling cancer growth, and offering an improved cardiovascular safety profile. The oral therapy eliminates the need for injectable treatments administered by healthcare providers, offering greater convenience for patients. This launch marks a significant advancement in prostate cancer management in India, providing patients and doctors with a new, safe, cost-effective treatment option.

In June 2024, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. The acquisition strengthens AstraZeneca's portfolio, enabling the development of next-generation radio conjugates that offer more targeted therapies, potentially replacing traditional chemotherapy and radiotherapy treatments. Fusion Pharmaceuticals, a Canada-based clinical-stage oncology company, specializes in therapies for prostate cancer, particularly targeting metastatic castration-resistant prostate cancer (mCRPC).

Major players in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prostate cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer therapeutics market consists of revenues earned by entities by providing services such as medical consultation services, diagnostic services, psychosocial support, clinical trials access, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer therapeutics market also includes sales of hormone therapy medications, chemotherapy drugs, immunotherapy products, and targeted therapy drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy; Other Therapies
2) By Drug Class: Androgen Receptor Inhibitors; GnRH Receptor Antagonists; PARP Inhibitors; Immune Checkpoint Inhibitors; Other Drug Classes
3) By Route Of Administration: Oral; Injectable
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Sales
5) By End User: Clinics; Hospitals; Other End Users
Subsegments:
1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists; LHRH Antagonists; Anti-Androgens; Androgen Synthesis Inhibitors
2) By Chemotherapy: Docetaxel; Cabazitaxel; Mitoxantrone; Combination Chemotherapy Regimens
3) By Immunotherapy: Sipuleucel-T; Immune Checkpoint Inhibitors; Cancer Vaccines; Cytokine-Based Therapies
4) By Targeted Therapy: PARP Inhibitors; Radioligand Therapy; Tyrosine Kinase Inhibitors
5) By Other Therapies: Radiotherapy; Bone-Targeted Therapies; Cryotherapy; High-Intensity Focused Ultrasound
Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35580

1. Executive Summary

2. Prostate Cancer Therapeutics Market Characteristics

3. Prostate Cancer Therapeutics Market Trends And Strategies

4. Prostate Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Prostate Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Prostate Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Prostate Cancer Therapeutics Market Growth Rate Analysis
5.4. Global Prostate Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Prostate Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Prostate Cancer Therapeutics Total Addressable Market (TAM)

6. Prostate Cancer Therapeutics Market Segmentation

6.1. Global Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Other Therapies
6.2. Global Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Androgen Receptor Inhibitors
GnRH Receptor Antagonists
PARP Inhibitors
Immune Checkpoint Inhibitors
Other Drug Classes
6.3. Global Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.4. Global Prostate Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Sales
6.5. Global Prostate Cancer Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinics
Hospitals
Other End Users
6.6. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Lhrh Antagonists
Anti-Androgens
Androgen Synthesis Inhibitors
6.7. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Docetaxel
Cabazitaxel
Mitoxantrone
Combination Chemotherapy Regimens
6.8. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sipuleucel-T
Immune Checkpoint Inhibitors
Cancer Vaccines
Cytokine-Based Therapies
6.9. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Parp Inhibitors
Radioligand Therapy
Tyrosine Kinase Inhibitors
6.10. Global Prostate Cancer Therapeutics Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Radiotherapy
Bone-Targeted Therapies
Cryotherapy
High-Intensity Focused Ultrasound

7. Prostate Cancer Therapeutics Market Regional And Country Analysis

7.1. Global Prostate Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Prostate Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prostate Cancer Therapeutics Market

8.1. Asia-Pacific Prostate Cancer Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prostate Cancer Therapeutics Market

9.1. China Prostate Cancer Therapeutics Market Overview
9.2. China Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prostate Cancer Therapeutics Market

10.1. India Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prostate Cancer Therapeutics Market

11.1. Japan Prostate Cancer Therapeutics Market Overview
11.2. Japan Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prostate Cancer Therapeutics Market

12.1. Australia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prostate Cancer Therapeutics Market

13.1. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prostate Cancer Therapeutics Market

14.1. South Korea Prostate Cancer Therapeutics Market Overview
14.2. South Korea Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prostate Cancer Therapeutics Market

15.1. Western Europe Prostate Cancer Therapeutics Market Overview
15.2. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prostate Cancer Therapeutics Market

16.1. UK Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prostate Cancer Therapeutics Market

17.1. Germany Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prostate Cancer Therapeutics Market

18.1. France Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prostate Cancer Therapeutics Market

19.1. Italy Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prostate Cancer Therapeutics Market

20.1. Spain Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prostate Cancer Therapeutics Market

21.1. Eastern Europe Prostate Cancer Therapeutics Market Overview
21.2. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prostate Cancer Therapeutics Market

22.1. Russia Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prostate Cancer Therapeutics Market

23.1. North America Prostate Cancer Therapeutics Market Overview
23.2. North America Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prostate Cancer Therapeutics Market

24.1. USA Prostate Cancer Therapeutics Market Overview
24.2. USA Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prostate Cancer Therapeutics Market

25.1. Canada Prostate Cancer Therapeutics Market Overview
25.2. Canada Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prostate Cancer Therapeutics Market

26.1. South America Prostate Cancer Therapeutics Market Overview
26.2. South America Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prostate Cancer Therapeutics Market

27.1. Brazil Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prostate Cancer Therapeutics Market

28.1. Middle East Prostate Cancer Therapeutics Market Overview
28.2. Middle East Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prostate Cancer Therapeutics Market

29.1. Africa Prostate Cancer Therapeutics Market Overview
29.2. Africa Prostate Cancer Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Prostate Cancer Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Prostate Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prostate Cancer Therapeutics Market Competitive Landscape And Company Profiles

30.1. Prostate Cancer Therapeutics Market Competitive Landscape
30.2. Prostate Cancer Therapeutics Market Company Profiles
- 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Prostate Cancer Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Astellas Pharma Inc.
31.3. Jiangsu Hengrui Medicine Co. Ltd.
31.4. Telix Pharmaceuticals
31.5. Bayer AG
31.6. Curium Pharma SAS
31.7. Dendreon Pharmaceuticals
31.8. Myovant Sciences GmbH
31.9. Clovis Oncology Inc.
31.10. Ipsen S.A.
31.11. Veru Inc.
31.12. Bristol-Myers Squibb Company
31.13. F. Hoffmann-La Roche Ltd
31.14. Dendreon Pharmaceuticals LLC
31.15. Pfizer Inc.

32. Global Prostate Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prostate Cancer Therapeutics Market

34. Recent Developments In The Prostate Cancer Therapeutics Market

35. Prostate Cancer Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Prostate Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Prostate Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Prostate Cancer Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer